Pfizer signs $500M deal with Enodia to develop Sec61 protein degraders

Pfizer has entered a licensing and research collaboration with Enodia Therapeutics, valued at up to $500 million, to discover and develop inhibitors of the Sec61 protein‑translocation channel.

The Sec61 channel controls the movement of proteins to the cell surface. By blocking this pathway, the companies aim to prevent disease‑driving proteins from reaching their targets and promote their degradation.

Under the agreement, Enodia will use its platform to generate candidate molecules, while Pfizer will assume responsibility for clinical testing, manufacturing, regulatory filings, and commercial launch. The deal includes an undisclosed upfront payment, milestone payments tied to research and sales, and tiered royalties on net sales.

The partnership follows Eli Lilly's recent $870 million pact with Gate Bioscience in the same Sec61 space, highlighting growing industry interest in protein degrader technologies.